Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EBMT 2019 | Side effects of CAR T-cell therapy

Michael Schmitt • 10 Apr 2019
EBMT 2019
Lymphoma Non-Hodgkin Lymphoma CAR-T

Michael Schmitt, MHBA, of University Hospital Heidelberg, Germany, explores the side effects of CD19 CAR T-cell therapy in patients with acute- and non-Hodgkin lymphoma. Prof. Schmitt was speaking at the European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting 2019, held in Frankfurt, Germany.

More from Michael Schmitt

Pros and cons of autologous and allogeneic CAR-Ts 2:46
Pros and cons of autologous and allogeneic CAR-Ts
Michael Schmitt • 7 Feb 2022
Exciting developments in the CAR space: novel target antigens, CAR-NKs & switchable CAR-Ts 4:25
Exciting developments in the CAR space: novel target antigens, CAR-NKs & switchable CAR-Ts
Michael Schmitt • 7 Feb 2022
Preparing for the commercialization of CAR-T products 4:17
Preparing for the commercialization of CAR-T products
Michael Schmitt • 7 Feb 2022
CD19 CAR T-cell therapy for lymphoma 2:55
CD19 CAR T-cell therapy for lymphoma
Michael Schmitt • 26 Apr 2019

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals